title: Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease.
abstract: Cardiovascular disease (CVD) is a leading cause of mortality in the Western World. The development and onset of disease can be attributed to many risk factors including genetic susceptibility, diabetes, obesity and atherosclerosis. Numerous studies highlight the production of advanced glycation endproducts (AGEs) and interaction with their receptor (RAGE) as playing a key pathogenic role. The AGEs-RAGE axis is thought to contribute to a proinflammatory environment inducing cellular dysfunction which cascades towards pathology. Mitochondrial dysfunction concurrently plays a role in these proinflammatory responses presenting excess reactive oxygen species (ROS) production under pathological conditions. This ROS release can exacerbate the production of AGEs fuelling the fire somewhat. However, the AGEs-RAGE axis may influence mitochondrial function independently of inflammation. Therefore instigation of the AGEs-RAGE axis may facilitate spiralling towards pathology on many fronts including CVD development.
authors.affiliation: Department of Glycation and Diabetic Complications, Mater Research, Brisbane, Queensland 4102, Australia. mward@mmri.mater.org.au
authors.forename: Micheal S
authors.initials: MS
authors.lastname: Ward
authors.forename: Amelia K
authors.initials: AK
authors.lastname: Fortheringham
authors.forename: Mark E
authors.initials: ME
authors.lastname: Cooper
authors.forename: Josephine M
authors.initials: JM
authors.lastname: Forbes
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D008928:Mitochondria / Q000378:metabolism*; D012307:Risk Factors
chemical_list: D017127:Glycation End Products, Advanced